SG11201912110YA - Novel peptide and pharmaceutical composition for treatment of eye diseases comprising same novel peptide as active ingredient - Google Patents

Novel peptide and pharmaceutical composition for treatment of eye diseases comprising same novel peptide as active ingredient

Info

Publication number
SG11201912110YA
SG11201912110YA SG11201912110YA SG11201912110YA SG11201912110YA SG 11201912110Y A SG11201912110Y A SG 11201912110YA SG 11201912110Y A SG11201912110Y A SG 11201912110YA SG 11201912110Y A SG11201912110Y A SG 11201912110YA SG 11201912110Y A SG11201912110Y A SG 11201912110YA
Authority
SG
Singapore
Prior art keywords
novel peptide
treatment
pharmaceutical composition
active ingredient
eye diseases
Prior art date
Application number
SG11201912110YA
Inventor
Taegon Baik
Taek-Soo Kim
Dae-Seong Lim
Deuk-Young Goo
Original Assignee
Yuyu Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yuyu Pharma Inc filed Critical Yuyu Pharma Inc
Publication of SG11201912110YA publication Critical patent/SG11201912110YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
SG11201912110YA 2017-05-17 2018-05-17 Novel peptide and pharmaceutical composition for treatment of eye diseases comprising same novel peptide as active ingredient SG11201912110YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170061250 2017-05-17
PCT/KR2018/005673 WO2018225961A1 (en) 2017-05-17 2018-05-17 Novel peptide and pharmaceutical composition for treatment of eye diseases comprising same novel peptide as active ingredient

Publications (1)

Publication Number Publication Date
SG11201912110YA true SG11201912110YA (en) 2020-01-30

Family

ID=64566301

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201912110YA SG11201912110YA (en) 2017-05-17 2018-05-17 Novel peptide and pharmaceutical composition for treatment of eye diseases comprising same novel peptide as active ingredient

Country Status (12)

Country Link
US (1) US20210024577A1 (en)
EP (1) EP3643723A4 (en)
JP (2) JP2020520372A (en)
KR (2) KR102287226B1 (en)
CN (1) CN110945012A (en)
AU (1) AU2018281617B2 (en)
BR (1) BR112019024040A2 (en)
CA (1) CA3063842A1 (en)
MX (1) MX2019013799A (en)
RU (1) RU2766160C2 (en)
SG (1) SG11201912110YA (en)
WO (1) WO2018225961A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110945012A (en) * 2017-05-17 2020-03-31 株式会社柳柳制药 Novel peptide and pharmaceutical composition for treating ocular diseases comprising the same as active pharmaceutical ingredient
US11613558B2 (en) 2018-11-14 2023-03-28 Yuyu Pharma, Inc. Peptides and pharmaceutical compositions for treating eye diseases
TW202031675A (en) * 2018-11-14 2020-09-01 南韓商柳柳製藥股份有限公司 Peptides and pharmaceutical compositions for treating eye diseases
KR20200134175A (en) * 2019-05-21 2020-12-01 주식회사 아이바이오코리아 Novel peptide compound or pharmaceutically acceptable salt thereof
KR20210104460A (en) * 2020-02-17 2021-08-25 주식회사 아이바이오코리아 A Method for preparing peptides using by solid phase synthesis
US20230146455A1 (en) * 2020-03-05 2023-05-11 Yuyu Pharma, Inc. Treatment of inflammatory diseases with peptides and pharmaceutical compositions
WO2023113300A1 (en) * 2021-12-13 2023-06-22 주식회사 아이바이오코리아 Composition for treating macular degeneration comprising novel peptide
KR102593936B1 (en) * 2021-12-13 2023-10-27 주식회사 아이바이오코리아 Composition for treating macular degeneration comprising novel peptides
KR102587729B1 (en) * 2023-02-27 2023-10-12 주식회사 아이바이오코리아 Composition for treating diabetic retinopathy comprising peptides

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037135A (en) * 1992-08-07 2000-03-14 Epimmune Inc. Methods for making HLA binding peptides and their uses
WO2007117444A2 (en) * 2006-03-31 2007-10-18 Yinghe Hu Protein detection by aptamers
US20090131303A1 (en) * 2007-11-16 2009-05-21 Bor-Shyue Hong Methods and compositions for treating dry eye
JP4490498B2 (en) * 2008-09-30 2010-06-23 新田ゼラチン株式会社 Disease inhibitor
JP6163482B2 (en) * 2011-05-27 2017-07-12 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ Crystalline form of cyclosporin A, process for its preparation and process for its use
KR20140099526A (en) * 2011-11-30 2014-08-12 자이겐 인플라메이션 리미티드 Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of dry eye syndrome
KR101438744B1 (en) * 2012-08-02 2014-09-15 전남대학교산학협력단 Compositions for Preventing or Treating of Dry Eyes or Inflammatory Eye Surface Diseases Comprising Adiponectin as Active Ingredient
KR101721059B1 (en) * 2014-12-26 2017-03-30 주식회사 아이바이오코리아 Pharmaceutical composition for preventing or treating ocular surface disease
KR101690539B1 (en) 2015-07-30 2016-12-29 주식회사 아이바이오코리아 Pharmaceutical composition for preventing or treating dry eye
CN109310731B (en) * 2016-04-08 2022-03-29 韩国视角生物株式会社 Extracellular matrix-derived peptide of chondrocyte
KR101798183B1 (en) * 2016-04-08 2017-11-15 주식회사 아이바이오코리아 Pharmaceutical composition for preventing or treating dry eye
KR101795653B1 (en) * 2016-05-19 2017-11-09 인제대학교 산학협력단 Composition for inhibiting angiogenesis comprising chimeric protein of collagen type II peptide-Aflibercept
CN110945012A (en) * 2017-05-17 2020-03-31 株式会社柳柳制药 Novel peptide and pharmaceutical composition for treating ocular diseases comprising the same as active pharmaceutical ingredient
TW202031675A (en) * 2018-11-14 2020-09-01 南韓商柳柳製藥股份有限公司 Peptides and pharmaceutical compositions for treating eye diseases
US20230146455A1 (en) * 2020-03-05 2023-05-11 Yuyu Pharma, Inc. Treatment of inflammatory diseases with peptides and pharmaceutical compositions

Also Published As

Publication number Publication date
WO2018225961A1 (en) 2018-12-13
CA3063842A1 (en) 2019-12-09
KR102498428B1 (en) 2023-02-20
RU2766160C2 (en) 2022-02-08
KR102287226B1 (en) 2021-08-11
KR20180126406A (en) 2018-11-27
JP2023098936A (en) 2023-07-11
JP2020520372A (en) 2020-07-09
KR20210097670A (en) 2021-08-09
EP3643723A4 (en) 2021-03-31
AU2018281617B2 (en) 2022-06-30
BR112019024040A2 (en) 2020-09-24
CN110945012A (en) 2020-03-31
US20210024577A1 (en) 2021-01-28
RU2019141646A3 (en) 2021-07-28
EP3643723A1 (en) 2020-04-29
RU2019141646A (en) 2021-06-17
AU2018281617A1 (en) 2019-12-05
MX2019013799A (en) 2020-08-13

Similar Documents

Publication Publication Date Title
SG11201912110YA (en) Novel peptide and pharmaceutical composition for treatment of eye diseases comprising same novel peptide as active ingredient
ZA202004025B (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
MX2021004110A (en) Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n' -(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl] ethane-1,2-diamine.
SG11202106160WA (en) Pharmaceutical composition for prevention or treatment of cancer comprising weissella cibaria wikim28 as active ingredient
EP3498279A4 (en) Pharmaceutical composition comprising amodiaquine and anti-diabetes drug as effective ingredient for prevention or treatment of diabetes
EP3336100A4 (en) Peptide having effect of preventing or treating central nervous system diseases and pharmaceutical composition for preventing and treating central nervous system diseases, containing same as active ingredient
PT3604304T (en) Pyrrolo-pyridine derivative compound, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of protein kinase-related diseases
IL279397A (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
IL291168A (en) Heteroarylamidopyridinol derivative and pharmaceutical composition comprising same as active ingredient for prevention or treatment of autoimmune disease
EP3713553A4 (en) Compositions and methods for treatment of eye diseases
SG11202104178TA (en) Peptides and pharmaceutical compositions for treating eye diseases
IL270159B (en) Nanostructured formulations for the delivery of silibinin and other active ingredients for treating ocular diseases
EP3311817A4 (en) Pharmaceutical composition for preventing and treating dry eye diseases, containing imatinib as active ingredient
EP3643302C0 (en) Composition containing sesquiterpene derivative as active ingredient for prevention or treatment of muscle diseases
SG11202106163RA (en) Pharmaceutical composition for prevention or treatment of cancer comprising lactobacillus sakei wikim30 as active ingredient
EP3603656A4 (en) Pharmaceutical composition for prevention or treatment of gynecological diseases containing extract of sarcodon imbricatus as active ingredient
EP3167893A4 (en) Pharmaceutical composition containing spirulina maxima extract as active ingredient for preventing and treating retinal diseases
EP3468540A4 (en) Pharmaceutical compositions and methods for treatment of pain
EP3362096A4 (en) Ophthalmic treatment composition and vehicle for delivery of pharmaceutical substances or therapeutic agents
EP3881849A4 (en) Composition comprising aptamer as active ingredient for treatment and prevention of degenerative brain disease
EP3603659A4 (en) Pharmaceutical composition for prevention or treatment of inflammatory respiratory disease, with fusion protein of cell permeable peptide and ctctla4 peptide contained as effective ingredient therein
EP3730513A4 (en) Peptide and pharmaceutical compositions of same for use as an antimicrobial and in cancer treatment
KR102091567B9 (en) Pharmaceutical composition for prevention or treatment of brain injury comprising the osteopontin protein fragment as an active ingredient
EP3530269A4 (en) Pharmaceutical composition for preventing or treating diabetes and/or hyperlipidemia comprising midorine or pharmaceutically acceptable salt thereof as active ingredient
EP3187179A4 (en) Pharmaceutical composition for prophylaxis and/or treatment of corneal and conjunctival diseases or presbyopia containing stilbene compound as active ingredient